ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/autologous-CAR-T-cell-therapy-BCMA-targeting
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/autologous-CAR-T-cell-therapy-BCMA-targeting
6
trial(s) found.
NCT06577025
Haem
Phase 2
Recruiting
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination With Daratumumab SC (Tal-D) and Teclistamab SC in Combination With Daratumumab SC (Tec-D) Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (
aMMbition
)
anti-CD38 monoclonal antibody
autologous CAR-T-cell therapy,BCMA-targeting
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
NCT06550895
Haem
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (
MonumenTAL-8
)
autologous CAR-T-cell therapy,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05666700
Haem
Phase 1
Recruiting
CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study (
CARAMEL
)
CAR-T-cell therapy
CAR-T-cell therapy,BCMA-targeting
Ciltacabtagene Autoleucel
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,BCMA-targeting
cancer therapy
cancer therapy,BCMA-targeting
cell therapy
+ autologous CAR-T-cell therapy,BCMA-targeting
Multiple myeloma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05257083
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (
CARTITUDE-6
)
anti-CD38 monoclonal antibody
autologous CAR-T-cell therapy,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05201781
Haem
Phase 4
Recruiting
Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel (
68284528MMY4002--CR109123
)
autologous CAR-T-cell therapy,BCMA-targeting
Multiple myeloma
NCT06045806
Haem
Phase 3
Active not recruiting
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (
KarMMa-9
)
autologous CAR-T-cell therapy,BCMA-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (5)
Active not recruiting (1)
Recruitment Country and State
VIC (5)
NSW (3)
QLD (2)
WA (2)
SA (1)
Phase
Phase 1 (1)
Phase 2 (2)
Phase 3 (2)
Phase 4 (1)
Trial Type
Haem (6)
Cancer Therapy Class
BCMA
100%
cereblon
50%
CD38
33%
GPRC5D
33%
proteasome
33%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (5)
3004 - Melbourne, Southbank - Alfred Health (4)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
6150 - Murdoch - Fiona Stanley Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
4032 - Chermside - The Prince Charles Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy